Department of Health and Human Services March 20, 2024 – Federal Register Recent Federal Regulation Documents

Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
Document Number: 2024-05801
Type: Proposed Rule
Date: 2024-03-20
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present demonstrable difficulties for compounding (Demonstrable Difficulties for Compounding Lists or DDC Lists) under certain sections of the Federal Food, Drug, and Cosmetic Act. Additionally, the Agency is proposing to identify the first three categories of drug products on both DDC Lists. Drug products or categories of drug products that appear on the DDC Lists cannot qualify for certain statutory exemptions, and therefore may not be compounded under, either section 503A or section 503B, respectively.
Native Public Health Resilience
Document Number: 2024-05831
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, Indian Health Service
Native Public Health Resilience Planning
Document Number: 2024-05826
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, Indian Health Service
National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting
Document Number: 2024-05824
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, National Institutes of Health
Statement of Organization, Functions, and Delegations of Authority
Document Number: 2024-05871
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, Health Resources and Services Administration
Office of the Director, National Institutes of Health; Notice of Meeting
Document Number: 2024-05869
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, National Institutes of Health
Reorganization of the Office of Safety, Security and Asset Management
Document Number: 2024-05866
Type: Notice
Date: 2024-03-20
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
CDC has modified its structure. This notice announces the reorganization of the Office of Safety, Security and Asset Management (OSSAM). OSSAM retitled a component.
Government-Owned Inventions; Availability for Licensing
Document Number: 2024-05881
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, National Institutes of Health
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Government-Owned Inventions; Availability for Licensing
Document Number: 2024-05880
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, National Institutes of Health
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep
Document Number: 2024-05878
Type: Notice
Date: 2024-03-20
Agency: Department of Health and Human Services, National Institutes of Health
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Taurgen Malaria, Inc. (``Taurgen''), headquartered in Logan, UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen Therapeutics, LLC, which is also headquartered in Logan, UT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.